Stocks and Investing
Stocks and Investing
Tue, April 18, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Serge Belanger Reiterated (TRVI) at Strong Buy and Held Target at $8 on, Apr 18th, 2023
Serge Belanger of Needham, Reiterated "Trevi Therapeutics, Inc." (TRVI) at Strong Buy and Held Target at $8 on, Apr 18th, 2023.
Serge has made no other calls on TRVI in the last 4 months.
There are 2 other peers that have a rating on TRVI. Out of the 2 peers that are also analyzing TRVI, 0 agree with Serge's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Serge
- Mayank Mamtani of "B. Riley Securities" Initiated at Strong Buy and Held Target at $6 on, Wednesday, April 12th, 2023
- Sean Kim of "JonesTrading" Initiated at Strong Buy and Held Target at $7 on, Tuesday, March 14th, 2023
Contributing Sources